BODE Index Calculator

How to Use This Calculator

1. Enter BMI, FEV1 % predicted, mMRC dyspnea score (0–4), and 6-minute walk distance (m).
2. BODE score (0–10) and 4-year survival estimate display instantly.
3. Quartile Risk tab shows transplant threshold and rehab impact.
4. Professional tier adds exacerbation history and GOLD E group assessment.

Formula

Example

Frequently Asked Questions

• What is the BODE index for COPD? ▼
  The BODE index is a multidimensional composite score developed by Celli and colleagues, originally published in the New England Journal of Medicine in 2004, to predict mortality risk in patients with Chronic Obstructive Pulmonary Disease. The acronym stands for BMI (nutritional status), Obstruction (FEV1 % predicted), Dyspnea (mMRC dyspnea scale), and Exercise capacity (6-minute walk distance). Each component is scored on a sub-scale and the total BODE score ranges from 0 (best) to 10 (worst). The original study demonstrated that the BODE index was a substantially better predictor of all-cause and respiratory mortality than FEV1 alone. BODE quartiles divide patients into four risk groups: Q1 (score 0–2) with approximately 80% 4-year survival; Q2 (3–4) approximately 67%; Q3 (5–6) approximately 42%; Q4 (7–10) approximately 18%. Because BODE captures the systemic consequences of COPD beyond the airways — nutritional depletion, exercise intolerance, and dyspnea — it provides a more holistic prognostic assessment than any single spirometric measure. BODE is now incorporated into GOLD guidelines as a prognostic tool, and serial BODE measurements are used to monitor disease trajectory and treatment response.
• Why does BODE outperform FEV1 alone for prognosis? ▼
  COPD is now understood to be a systemic disease, not merely an airway disease, and FEV1 captures only one dimension of its impact. The landmark Celli et al. 2004 NEJM study of 625 COPD patients demonstrated that BODE predicted death from any cause and from respiratory causes with significantly higher C-statistic (area under the ROC curve) than FEV1 alone (0.74 vs 0.65 for all-cause mortality). The reason for this superiority lies in the independent prognostic contributions of each BODE component. Nutritional status (BMI ≤21) independently predicts higher mortality in COPD due to muscle wasting and cachexia. Exercise capacity (6-minute walk distance) reflects cardiovascular reserve, peripheral muscle function, and overall disease burden — domains entirely uncaptured by spirometry. Dyspnea (mMRC score) reflects the patient's functional impairment and correlates poorly with FEV1 in established COPD. Studies have also shown that improvements in BODE after pulmonary rehabilitation or lung volume reduction surgery predict survival benefit, while isolated FEV1 changes may not. GOLD 2024 continues to recommend BODE as the preferred prognostic index when comprehensive assessment is available. Several refinements — BODEx (replacing 6MWD with exacerbations), ADO (age-dyspnea-obstruction), and DOSE — have since been developed to address practical limitations.
• When should COPD patients be referred for lung transplant? ▼
  Lung transplantation referral should be considered for carefully selected COPD patients who have severe disease despite optimal medical therapy including smoking cessation, inhaled pharmacotherapy (LAMA + LABA ± ICS), and pulmonary rehabilitation. According to the International Society for Heart and Lung Transplantation (ISHLT) 2014 consensus guidelines, COPD patients should be referred for transplant evaluation when BODE index is 7 to 10, or any of the following: history of hospitalisation for acute hypercapnic respiratory failure (PaCO2 > 50 mmHg); FEV1 below 20% predicted with either DLCO below 20% predicted or homogeneous distribution of emphysema; resting hypoxaemia (PaO2 < 60 mmHg on room air) or hypercapnia (PaCO2 > 50 mmHg) not attributable to other causes; progressive disease despite maximum therapy with FEV1 declining >80 mL/year. BODE ≥7 specifically is associated with approximately 30–40% 2-year mortality — comparable to the pre-transplant mortality that justifies the procedure. Transplantation options for COPD include single lung transplant (most common), bilateral sequential lung transplant (better long-term outcomes, especially in younger patients), and bilateral lung transplant. BODE is not a listing criterion but a referral trigger; full evaluation includes cardiac assessment, body composition, psychosocial factors, and functional status.
• How does pulmonary rehab affect BODE score? ▼
  Pulmonary rehabilitation (PR) is the most evidence-based non-pharmacological intervention in COPD and produces measurable improvements in BODE index through its effects on multiple BODE components simultaneously. Published randomised controlled trials and the ATS/ERS Pulmonary Rehabilitation Statement demonstrate that PR typically improves the 6-minute walk distance by 50–80 metres (the minimum clinically important difference is approximately 35 metres), reduces mMRC dyspnea score by 1 grade, improves exercise capacity, and may modestly improve nutritional status through supervised exercise training and nutritional counselling. The combined effect is an average BODE score improvement of 1–2 points. Critically, improvements in BODE after pulmonary rehabilitation have been shown to predict reduced mortality: each 1-point reduction in BODE is associated with a 22% lower risk of death. A landmark RCT by Cote and Celli demonstrated that patients whose BODE improved after rehabilitation had significantly better survival than non-improvers, independent of baseline severity. For BODE Q4 patients (score 7–10), rehabilitation remains appropriate and can meaningfully improve quality of life and functional status even when spirometric improvements are modest. COPD patients in GOLD groups B and E particularly benefit from early PR referral.
• What is the difference between BODE, BODEx, ADO, and DOSE indices? ▼
  All four are multidimensional composite indices developed to improve prognostic accuracy beyond FEV1 alone in COPD, but they differ in components and practical applicability. BODE (Celli et al. 2004) uses BMI, FEV1% predicted, mMRC dyspnea, and 6-minute walk distance. Its limitation is that the 6-minute walk test requires supervised facilities, is time-consuming, and is not feasible in all clinical settings. BODEx replaces the 6-minute walk distance with exacerbation frequency (number of moderate-severe exacerbations in the past year), making it practical for primary care. BODEx retains similar prognostic accuracy to BODE and correlates well with mortality in published validation studies. The ADO index (Age, Dyspnea, Obstruction) was derived from a large European cohort and uses only three variables — age, mMRC score, and FEV1% — making it extremely simple and requiring no walking test. ADO showed excellent prognostic performance in the validation cohort. The DOSE index incorporates Dyspnea, Obstruction, Smoking status, and Exacerbation frequency, and was specifically validated for predicting health status and exacerbation risk. For clinical practice: BODE remains the reference standard for research and transplant planning; BODEx or ADO are practical alternatives in primary care; DOSE is useful for predicting future exacerbations. All four outperform FEV1 alone for mortality prediction.

Related Calculators